Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry
about
Challenges and advances in the assessment of the disposition of antibody-drug conjugatesIn vitro and in vivo evaluation of cysteine and site specific conjugated herceptin antibody-drug conjugatesChemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug ConjugatesRF1 attenuation enables efficient non-natural amino acid incorporation for production of homogeneous antibody drug conjugates.A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry.Workshop report: Crystal City V--quantitative bioanalytical method validation and implementation: the 2013 revised FDA guidance.Pharmacokinetic considerations for antibody drug conjugates.The impact of mass spectrometry on the study of intact antibodies: from post-translational modifications to structural analysis.Practical considerations for the pharmacokinetic and immunogenic assessment of antibody-drug conjugates.Assessment of the metabolism of therapeutic proteins and antibodies.Therapeutic applications of an expanded genetic code.Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug ConjugatesBioanalytical approaches for characterizing catabolism of antibody-drug conjugates.LC-MS-based quantification of intact proteins: perspective for clinical and bioanalytical applications.Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.Qualitative and quantitative characterization of protein biotherapeutics with liquid chromatography mass spectrometry.2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV): (Part 2 - Hybrid LBA/LCMS and input from regulatory agencies).Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates.Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates.A workflow for absolute quantitation of large therapeutic proteins in biological samples at intact level using LC-HRMS.Real-Time Analysis on Drug-Antibody Ratio of Antibody-Drug Conjugates for Synthesis, Process Optimization, and Quality ControlDecoupling stability and release in disulfide bonds with antibody-small molecule conjugates.Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics.Insights into antibody-drug conjugates: bioanalysis and biomeasures in discovery.Quantification of human mAbs in mouse tissues using generic affinity enrichment procedures and LC-MS detection.PK assays for antibody-drug conjugates: case study with ado-trastuzumab emtansine.Characterization of the drug-to-antibody ratio distribution for antibody-drug conjugates in plasma/serum.Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper.Antibody-drug conjugate bioanalysis using LB-LC-MS/MS hybrid assays: strategies, methodology and correlation to ligand-binding assays.Stabilizing a Tubulysin Antibody-Drug Conjugate To Enable Activity Against Multidrug-Resistant Tumors.Immunoprecipitation middle-up LC-MS for in vivo drug-to-antibody ratio determination for antibody-drug conjugates.Metal-bound claMP Tag inhibits proteolytic cleavage.Key bioanalytical measurements for antibody-drug conjugate development: PK/PD modelers' perspective.PK of immunoconjugate anticancer agent CMD-193 in rats: ligand-binding assay approach to determine in vivo immunoconjugate stability.Highlights from the 2014 Applied Pharmaceutical Analysis conference.Calculated conjugated payload from immunoassay and LC-MS intact protein analysis measurements of antibody-drug conjugate.Unconjugated payload quantification and DAR characterization of antibody-drug conjugates using high-resolution MS.Antibody-conjugated drug assay for protease-cleavable antibody-drug conjugates.Use of a charge reducing agent to enable intact mass analysis of cysteine-linked antibody-drug-conjugates by native mass spectrometry.
P2860
Q28085074-BCF08A33-6A7B-4F6D-9DA2-3ECDEB9E2535Q28538658-3117818A-DF0D-4846-9EBA-F24CFD419B59Q28828981-77C71346-B8D0-449F-8DD2-53361C91DCE2Q33780009-97C9B16E-6EBE-4649-A24D-1BBAC0408E87Q34099745-5D8D18A2-7E49-4CDF-8D2D-EDDE297227E2Q34359998-7F1B73F5-4C01-48AD-A5E3-EC3DAA358771Q35192897-BED9120D-47C9-4069-8D21-63D65C04E12DQ38022192-13D049A9-F061-471B-846B-278B7916B666Q38062785-41AD9AFA-3005-497B-BB80-E093439238B1Q38212929-9DB0CEFD-F7E9-478F-8B36-B580BC671307Q38217623-9F26A8CF-6962-4F4E-9435-8D08BAE9C23AQ38232022-FE20AB20-6B45-4778-8EFD-28382869D5E6Q38275051-D2620622-29C8-4ACA-9A85-4E9CDEF0DACAQ38557519-94422E18-DD2F-4631-8D3F-1F2913275C11Q38571078-46BB18C7-8AC6-4228-99D4-29E609DE964DQ38665164-BD3CA705-384F-4C8B-B7F9-EFADE3A8CA49Q38812885-6B86E6B7-DF4B-487B-B4FE-6673DAA057E1Q39010880-12727062-DA2D-4A1B-87C3-301507796611Q39090290-1B59331D-868B-4571-80CF-05197EA0ED81Q39408093-36BC96DF-A1F5-4BBC-AB50-D682F0CC9ADEQ39529153-5858C44E-4C3C-471C-B3DF-8999B5FD38B9Q41353023-FB3EC506-5308-4B8C-A869-EE1F8F605B7FQ42314398-E5FE311C-BEF0-41B4-9AA6-2419449D9FDAQ43751494-2221AE51-35F6-4C34-87F8-8D8506FB66EAQ43906882-8573DF1B-EDB0-4221-B6ED-D67A252514BFQ45000688-27448415-0CC8-442E-8E0C-95D59C7D0589Q45006316-2D109DCA-3FDF-44DD-B9B8-417A56E3010EQ45223731-F0942F42-1755-46DD-92B8-75F55DA6606DQ46522736-58FB532C-E0CB-403E-AB8E-647F3F94FED7Q46535634-E889E48F-7038-47BB-B695-2612DED42D2BQ46906336-C44C0882-8425-4E51-B9CA-50CE06829583Q50088579-11857642-7401-45CC-B778-01D6D68B0908Q50624935-9B0EC9BB-F6E1-4326-B7BD-FEECAD781610Q51021486-9D8F08A9-84CC-40E7-84B8-19D9D450DAF3Q51132501-C10FE816-9534-4CCE-9BD5-75F78E806FB3Q51270936-C726E30A-DE84-4C02-A100-5377673C1C63Q51451422-A78BCF49-DE66-49CF-99A3-E60A95BDCDDFQ51596990-E0924682-9B54-4593-B05E-09936630B709Q52897133-86F9EEE9-CE58-4CEB-83E1-1D984D5A50C4Q55425586-ED068F45-1A1A-466B-8A64-BF3BE2338742
P2860
Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry
description
im Mai 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 07 January 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2011
@uk
name
Characterization of intact ant ...... romatography–mass spectrometry
@en
Characterization of intact ant ...... romatography–mass spectrometry
@nl
type
label
Characterization of intact ant ...... romatography–mass spectrometry
@en
Characterization of intact ant ...... romatography–mass spectrometry
@nl
prefLabel
Characterization of intact ant ...... romatography–mass spectrometry
@en
Characterization of intact ant ...... romatography–mass spectrometry
@nl
P2093
P356
P1476
Characterization of intact ant ...... romatography-mass spectrometry
@en
P2093
Douglas Leipold
Helga Raab
Jakub Baudys
Lara Williams
Ola M Saad
Surinder Kaur
P356
10.1016/J.AB.2011.01.004
P407
P577
2011-01-07T00:00:00Z